论文部分内容阅读
目的 研究原发性肝癌患者血清内皮抑素水平与其临床病理因素的关系。方法 用自行制备的内皮抑素多克隆及单克隆抗体采用双抗体夹心ELISA法测定原发性肝癌患者血清内皮抑素水平。结果 血清内皮抑素水平在原发性肝癌患者及健康人分别为 (39.76± 15 .85 )ng/ml及 (2 8.5 8± 7.92 )ng/ml,原发性肝癌患者显著高于健康人 (F =7.2 3,P <0 .0 5 ) ;血清内皮抑素水平在原发性肝癌无远处转移与伴有远处转移患者分别为 (34.6 3± 12 .5 6 )ng/ml、(45 .0 7± 2 1.4 7)ng/ml,血清内皮抑素水平与肿瘤有无远处转移有关 (F =6 .97,P <0 .0 5 ) ;血清内皮抑素含量在肝癌肿块直径 >10cm为 (38.94± 16 .97)ng/ml,而在肿块直径小于 10cm的患者为 (2 9.6 2± 11.78)ng/ml,两者具有显著性差异 (F =6 .13,P <0 .0 5 )。结论 原发性肝癌患者血清内皮抑素水平显著增高并与肿瘤的大小及有无远处转移有关。
Objective To study the relationship between serum endostatin level and clinicopathological factors in patients with primary liver cancer. Methods The serum endostatin level in patients with primary liver cancer was determined by double antibody sandwich ELISA using polyclonal and monoclonal antibody of endostatin. Results The serum level of endostatin was significantly higher in patients with primary hepatocellular carcinoma and in healthy individuals (39.76 ± 15.85 ng / ml and (2.858 ± 7.92) ng / ml, respectively, and significantly higher in patients with primary hepatocellular carcinoma than in healthy individuals F = 7.23, P <0.05). Serum endostatin levels in patients with primary liver cancer without distant metastasis and with distant metastasis were (34.6 3 ± 12.56) ng / ml, ( 45 .0 7 ± 2 1.4 7) ng / ml, serum endostatin levels with or without distant metastasis (F = 6.97, P <0.05); serum endostatin levels in liver tumor mass diameter (38.94 ± 16.97) ng / ml for those with> 10 cm and (2 9.62 ± 11.78) ng / ml when the diameter of the tumor was less than 10 cm (F = 6.13, P <0 .0 5). Conclusions Serum endostatin levels in patients with primary liver cancer are significantly increased and are related to tumor size and distant metastasis.